ong term effects of COVID-19 in people with diabetes

Not Applicable

• Conditions: COVID-19 (SARS-CoV-2 infection) in people with diabetes; Infections and Infestations; COVID-19 (SARS-CoV-2 infection)

• Registration Number: ISRCTN14643181
• Lead Sponsor: HS Greater Glasgow and Clyde

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-05-24
• Last Update Posted: 20 February 2023
• Study Completion: 2024-10-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

People aged over 18 resident in Scotland and with prior diagnosis of type 1 or type 2 diabetes

Exclusion Criteria

Not able to read and write in English

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
COVID symptoms measured using Wellcome Trust COVID-19 questionnaire at baseline (all participants) and 1 year (cases only)

Secondary Outcome Measures

Name	Time	Method
<br> Measured at baseline (all participants in case cohort study) and 1 year (cases in case cohort study only)<br> 1. Bioimpedance measured using bioelectrical impedance analysis<br> 2. Pulmonary function measured using lung function test<br> 3. Grip strength measured using dynamometer<br> 4. Physical ability measured using walking test<br> 5. Diabetes Related Quality of Life (DQOL)<br> 6. Diabetes-Specific Emotional Distress (DDS-1)<br> 7. Quality of life (EQ5D)<br> 8. HbA1c, LFTs, lipids, U&Es, inflammatory (e.g. CRP), vascular (t-PA, vWF) and cardiac (hs troponin, NT proBNP) biomarkers measured using blood test<br>